golcadomide (CC-99282) / BMS - LARVOL DELTA

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results (ASH 2025) - P1/2, P3 | "Median number of prior treatments was 4.5 (range, 2–6) in Part A and 3 (range, 1–12)in Part B Cohort D. Approximately one-third of the treated patients were exposed to prior T-cell–redirecting therapy, approximately one-third had prior lenalidomide (len) exposure, and approximatelyone-third were refractory to the last regimen received. A higher ORR/CRR and similar tolerability were observed with GOLCA 0.4 mg + R vsGOLCA 0.2 mg + R, including in patients with prior len-based and/or T-cell–redirecting treatment. Thesedata support continued development of GOLCA 0.4 mg + R as a fixed-duration, chemotherapy-free,outpatient option in the ongoing Phase 3 GOLSEEK-4 study in 2L+ FL (NCT06911502)."

Clinical • P1/2 data • Cardiovascular • Febrile Neutropenia • Follicular Lymphoma • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Lymphoma • Neutropenia • Pulmonary Embolism • Respiratory Diseases • CRBN • IKZF1

Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) (ASH 2025) - P1 | "In Arm 2, ptsreceived intravenous obinutuzumab pretreatment on C1D1 and Glofit on C1D8 (2.5mg), D15 (10mg),then D1 of subsequent cycles (30mg); oral Golca was given daily from C2 or C3 onwards (D1–10; 21-daycycles) in dose escalation (0.2 or 0.4mg). Early data suggest Mosun/Glofit+Golca is an active regimen with a manageable safetyprofile consistent with the risks of individual agents. No new safety signals were observed; CRS eventswere low grade. Neutropenia was the most common overlapping toxicity and was manageable withprophylactic and therapeutic G-CSF."

Clinical • Combination therapy • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Cognitive Disorders • Developmental Disorders • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Herpes Zoster • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • Varicella Zoster • CRBN • IKZF1

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results (ASH 2025) - P1/2 | "GOLCA+ R induced a decrease in circulating tumor DNA across tumor variants. These data support the ongoingdevelopment of GOLCA + R in patients with R/R non-Hodgkin lymphoma."

Clinical • P1/2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases • CRBN • IKZF1

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results (ASH 2025) - P1, P3 | "GOLCA drivesthe closed, active conformation of cereblon to induce rapid and deep degradation of Ikaros and Aiolos,leading to direct cell killing (agnostic of cell of origin [COO]) and immunomodulatory activity.CC-220-DLBCL-001 (NCT04884035) is an ongoing Phase 1b, open-label, multicenter trial to assess safetyand preliminary efficacy of GOLCA+R-CHOP in previously untreated a-BCL. GOLCA+R-CHOP demonstrated a predictable and manageablesafety profile with low rates of non-hematologic AEs; addition of GOLCA to R-CHOP did not compromiseSOC delivery. These data continue to show that GOLCA 0.4mg, when added to SOC Tx, has a potential tocure more previously untreated pts with HR LBCL and support the ongoing Phase 3 trial, GOLSEEK-1, inthis population (NCT06356129)."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Gastrointestinal Disorder • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • CRBN • IKZF1

GOLCADOMIDE (GOLCA), A CEREBLON E3 LIGASE MODULATOR (CELMOD™) AGENT ± RITUXIMAB (R), IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): UPDATED PHASE 1/2 STUDY RESULTS (EHA 2025) - P1/2 | "Primary objectives included safety and RP2D determination.As of 30 Dec 2024, 12 pts received GOLCA in Part A, and 22 and 38 received 0.2mg and 0.4mg GOLCA+R in Part B. In Part B, median time (range) from initial diagnosis was 59 mo (10-420), median prior Tx lines was 3 (1-12), 28% had prior T-cell-directed Tx, 30% had prior lenalidomide (len) and 30% were refractory to last Tx.In Part A, 4 pts completed 2 y of GOLCA, remaining in remission at last f/u; 8 discontinued (d/c) due to PD. With additional f/u, GOLCA continued to show promising efficacy with durable responses and no new safety signals. A higher ORR and similar tolerability were observed with GOLCA 0.4mg +R vs GOLCA and GOLCA 0.2mg +R, including in pts with prior len-based and/or T-cell-directed Tx. These data support continued development of GOLCA 0.4mg +R as a fixed-duration, chemo-free, outpatient option in R/R FL, to be evaluated in the Ph3 GOLSEEK-4 study."

Clinical • P1/2 data • Anemia • Febrile Neutropenia • Follicular Lymphoma • Immune Modulation • Immunology • Infectious Disease • Lymphoma • Neutropenia • Targeted Protein Degradation • CRBN • IKZF1

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Nathan Denlinger | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

GOLCADOMIDE, A CEREBLON E3 LIGASE MODULATOR (CELMoD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED PHASE 1/2 RESULTS (ICML 2025) - P1/2 | "As of 30 Dec 2024, 12 pts received GOLCA in Part A. 22 and 38 received 0.2 and 0.4 mg GOLCA+R in Part B; median (mdn; range) time from initial diagnosis was 59 months (mo) (10–420), mdn prior Tx lines was 3 (1–12; 28% had T-cell–directed Tx, 30% lenalidomide [len], and 30% were refractory to last Tx). With additional f/u, GOLCA continued to show promising efficacy with durable responses and no new safety signal in heavily pretreated pts with R/R FL, including pts with prior len and/or T-cell–directed Tx. GOLCA 0.4 mg +R will be evaluated in the Ph3 GOLSEEK-4 study as a fixed-duration, chemo-free, outpatient option in R/R FL."

Clinical • P1/2 data • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CRBN • IKZF1

GOLSEEK-1: Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (clinicaltrials.gov) - P3 | N=850 | Active, not recruiting | Sponsor: Celgene | Recruiting ➔ Active, not recruiting

Enrollment closed • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • MYC

GOLCADOMIDE (GOLCA), A CEREBLON E3 LIGASE MODULATOR (CELMOD™) AGENT, ± RITUXIMAB (R) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): UPDATED PHASE 1/2 STUDY RESULTS (EHA 2025) - P1/2 | "With additional f/u, GOLCA+R continued to demonstrate a manageable safety profile with no new safety signals. Durable responses were shown in heavily pre-treated patients with R/R DLBCL. Responses were independent of cell of origin and tumor microenvironment status."

Clinical • IO biomarker • P1/2 data • Anemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Immune Modulation • Immunology • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Respiratory Diseases • Targeted Protein Degradation • BCL2 • CRBN • IKZF1 • TP53

A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas (clinicaltrials.gov) - P1/2 | N=49 | Recruiting | Sponsor: The Lymphoma Academic Research Organisation | Not yet recruiting ➔ Recruiting

Enrollment open • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

Golcadomide (GOLCA; CC-99282), a Potential First-in-Class Oral CELMoD™ Agent, With R-CHOP, As First-line (1L) Therapy in Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial (SOHO 2024) - P1 | "The ongoing CC-220-DLBCL-001 trial of GOLCA+R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) (NCT04884035) has shown manageable safety and encouraging efficacy in untreated a-BCL. GOLCA+R-CHOP had a high rate of durable CMRs irrespective of cell of origin; promising 12-month progression-free survival, including in HR patients; and a manageable safety profile without compromising curative treatment. This supports the randomized phase 3 GOLSEEK-1 trial of untreated HR LBCL."

Clinical • P1 data • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

GOLSEEK-1: A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY OF GOLCADOMIDE + R-CHOP VERSUS PLACEBO + R-CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED, HIGH-RISK, LARGE B-CELL LYMPHOMA (ICML 2025) - P3 | "Introduction: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is standard treatment (Tx) for diffuse large B-cell lymphoma (DLBCL) and is curative in ≈60–70% of patients (pts)...In the phase 1b study CC-220-DLBCL-001, GOLCA + R-CHOP was well tolerated, with promising activity and combinability and high rates of durable responses irrespective of COO in pts with previously untreated aggressive BCL, including HR pts...Key secondary endpoints include PFS in non–high-grade BCL, event-free survival, independently assessed complete metabolic response, undetectable minimal residual disease by PhasED-Seq, and overall survival. This study is recruiting globally at 309 sites in 36 countries."

Clinical • P3 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • CRBN • IKZF1

SAFETY AND EFFICACY OF GOLCADOMIDE, A POTENTIAL FIRST-IN-CLASS CELMOD AGENT ± RITUXIMAB IN A PHASE 1/2 OPEN-LABEL STUDY OF PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) (EHA 2024) - P1/2 | "GOLCA±RTX showed encouraging efficacy in heavily pretreated pts with R/R FL, including in pts with LEN-refractory disease and post CAR T cell relapses. Longer follow-up with GOLCA monotherapy shows responsesare durable. GOLCA can be safely combined with RTX, with a similar safety profile to that previously reportedfor GOLCA monotherapy."

Clinical • P1/2 data • Cardiovascular • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Oncology • Pulmonary Embolism • Respiratory Diseases • Targeted Protein Degradation • CRBN • IKZF1

GOLCADOMIDE (GOLCA [CC-99282]), A POTENTIAL FIRST-IN-CLASS ORAL CELMOD™ AGENT, PLUS R-CHOP IN PATIENTS (PTS) WITH UNTREATED AGGRESSIVE B-CELL LYMPHOMA (A-BCL): SAFETY AND 12-MONTH EFFICACY RESULTS (EHA 2024) - P1 | "CC-220-DLBCL-001 (NCT04884035) is an ongoing phase 1b,open-label, multicenter, dose escalation/expansion trial to assess safety and preliminary 1L GOLCA+R-CHOPefficacy in a-BCL. GOLCA at DL1 with R-CHOP resulted in a high rate of durable CMRs irrespective of COO and a promising 12-month PFS in the overall and HR populations. GOLCA+R-CHOP demonstrated a manageable safety profile; theaddition of GOLCA to R-CHOP did not compromise curative treatment. These data support the initiation of therandomized phase 3 trial GOLSEEK-1 of GOLCA+R-CHOP versus R-CHOP as 1L treatment in pts with HR DLBCL."

Clinical • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • IKZF1

Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL) (ASH 2024) - P1 | "CC-220-DLBCL-001 (NCT04884035) is an ongoing phase 1b, open-label, multicenter, dose-escalation/expansion trial to assess safety and preliminary 1L GOLCA + R-CHOP efficacy in a-BCL. Although pt numbers were small, the data suggest that 0.4 mg is efficacious in high-risk ctDNA and high-genomic risk pts, independent of COO, and support the 0.4 mg GOLCA + R-CHOP regimen in the randomized phase 3 trial GOLSEEK-1. Interim MRD- may play a role in future adaptive trial designs."

Minimal residual disease • Residual disease • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Targeted Protein Degradation • CRBN • IKZF1 • TP53

Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment (clinicaltrials.gov) - P1 | N=29 | Completed | Sponsor: Celgene | Recruiting ➔ Completed

Trial completion • Hepatology

GOLSEEK-2: A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: Celgene | Recruiting ➔ Active, not recruiting

Enrollment closed • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Trial primary completion date: Dec 2025 ➔ Dec 2027

Trial primary completion date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Golcadomide: “Golcadomide + R-CHOP in 1L LBCL led to high CMR rates and encouraging 2-year PFS rate of 79%” Large B-cell lymphoma (Bristol-Myers Squibb) - Virtual Investor Presentation on Hematology Programs: “Golcadomide + R-CHOP demonstrated a predictable and manageable safety profile”

P1 data • Hematological Malignancies • Large B Cell Lymphoma • Oncology

Golcadomide demonstrates potent antiproliferative activity in T-cell lymphoma via degradation of IKZF1 and IKZF3 (ASH 2025) - "Overexpression of thesemutants effectively protected the cells from golcadomide-induced antiproliferation in all tested modelsand also conferred resistance against lenalidomide in lenalidomide-sensitive cell lines.In summary, these findings support the continued development of golcadomide as a promisingtherapeutic for T-cell lymphomas. Its potent efficacy across multiple TCL subtypes and mechanismsinvolving IKZF1 and IKZF3 degradation highlight a novel strategy to address unmet clinical need in thischallenging disease."

Adult T-Cell Leukemia-Lymphoma • B Cell Lymphoma • Cutaneous T-cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • T Cell Non-Hodgkin Lymphoma • Targeted Protein Degradation • CRBN • IKZF1 • IKZF3

IQGAP1 is a novel non-degraded substrate of CELMoDs and involved in trafficking of immune cells to the tumor microenvironment (ASH 2025) - "Introduction: Cereblon E3 ligase modulating drugs (CELMoDs) represent a novel class ofimmunomodulatory agents that target IKZF1 and IKZF3 for degradation, building upon earliergenerations such as Thalidomide and Avadomide...Similarfindings were observed in patients treated with Golcadomide (Golca), a next generation CELMoDcurrently under clinical investigation for DLBCL, follicular lymphoma, and T cell lymphoma, and wererecapitulated in a genetically engineered humanized cereblon-DLBCL mouse model, highlighting thetranslational significance of CELMoD-induced immune modulation... This study uncovers a novel mechanism by which Golca binding to CRBN mediates enhancedubiquitination of three specific lysine residues on IQGAP1. This modification increased IQGAP1'sinteraction with Rac, CDC42 and actin, thereby promoting directional immune cell migration. Ourfindings provide the first description of IQGAP1 as a non-degraded CELMoD substrate, directly linking itsbiological..."

Biomarker • Immune cell • Tumor microenvironment • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Immune Modulation • Immunology • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • Targeted Protein Degradation • CDC42 • CRBN • IKZF1 • IKZF3 • IQGAP1

Challenges in comparing outcomes of frontline clinical trials for diffuse large B-cell lymphoma patients selected based on the international prognostic index: A real-world analysis from the danish lymphoma registry (ASH 2025) - P3 | "This study aimed to present real-world outcomes among patients treated with R-CHOP/R-CHOP-like (+/-etoposide) regimens who met the inclusion criteria for four currently ongoing phase 3 trials: GOLSEEK-1(NCT06356129, R-CHOP+golcadomide vs. R-CHOP+placebo), SKYGLO (NCT06047080,glofitamab+polatuzumab+R-CHP vs. polatuzumab-R-CHP), ENGINE-1 (NCT03263026, enzastaurine+R-CHOP vs. R-CHOP), and ZUMA-23 (NCT05605899, axi-cel vs. standard of care 1st line therapy). This retrospective analysis of 3,475 newly diagnosed DLBCL patients assessed real-worldoutcomes and the impact of trial eligibility criteria across four ongoing frontline trials. Variations in IPIthresholds and clinical/laboratory requirements resulted in substantial differences in the proportion oftrial-eligible patients. Among the analyzed trials, ZUMA-23 had the most stringent eligibility criteria,resulting in the lowest eligibility rate and the exclusion of many younger individuals."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma

Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma (ASH 2025) - P3 | "Rituximab, cyclophosphamide, doxorubicin, vincristine,and prednisone (R-CHOP) is the standard first-line treatment for DLBCL, achieving cure rates inapproximately 60–70% of patients...GOLCA drivesthe closed, active conformation of cereblon to induce rapid and deep degradation of Ikaros and Aiolos,leading to direct cell killing (agnostic of cell of origin [COO]) and immunomodulatory activity.In the Phase 1b study CC-220-DLBCL-001, GOLCA in combination with R-CHOP demonstrated apredictable and manageable safety profile with high rates of durable responses, irrespective of COO, inpreviously untreated aggressive B-cell lymphomas (BCL), including promising activity in HR patients(Amzallag et al, ASH 2024, #579)...After a screening period of ≤4 weeks, patients will receive either GOLCA (0.4 mg) or placebo orallyonce daily for 7 consecutive days in each of 6 cycles, combined with R-CHOP every 21 days.The primary endpoint is progression-free survival (PFS) by investigator..."

Clinical • P3 data • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Epstein-Barr Virus Infections • Follicular Lymphoma • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type • ALK • BCL2 • CRBN • IKZF1

PlatΤform: A multicenter, multi-arm, academic platform trial evaluating novel agents and combinations in relapsed or refractory peripheral T-cell lymphomas (ASH 2025) - P1/2 | "Each sub-study has additional and specific inclusion and exclusion criteria.Sub-Studies: Two sub-studies are currently open:GolcAza: evaluates the combination of golcadomide and oral azacitidine in R/R follicular helper T-celllymphoma. PlaTform represents a novel academic initiative dedicated to R/R PTCL, designed toaccelerate therapeutic innovation in this underserved population.Acknowledgement: We wish to thank the patients and their families for their participation in the clinicaltrials, iOnctura for providing access to roginolisib, and Bristol-Myers Squibb for providing access togolcadomide and azacitidine."

Clinical • B Cell Lymphoma • Cutaneous T-cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoblastic Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • T-Cell Large Granular Lymphocyte Leukemia • PIK3CD

Golseek-4: A Phase 3, randomized study of golcadomide, a potential, first-in-class, oral CELMoD™ agent, plus rituximab versus Investigator's choice in patients with Relapsed/Refractory follicular lymphoma who have received ≥1 line of systemic therapy (ASH 2025) - P3 | "Patients randomized to IC will receive rituximab-lenalidomide (lenalidomide 20mg Days 1–21 every 28 days plus rituximab) for 5 cycles followed by lenalidomide monotherapy for 7cycles (total of 12 cycles) or rituximab-chemotherapy (R-CHOP or R-Bendamustine) for 6 cycles.Randomization will be stratified by progression of disease within 24 months vs >24 months from initialtherapy, number of prior systemic regimens (2L vs 3L+), and comparator IC regimen. Patients will be followed for up to five years from the last patient's first visit.GOLSEEK-4 will evaluate the safety and efficacy of golcadomide + rituximab as a fixed-duration,chemotherapy-free, outpatient treatment for patients with R/R FL, who have received ≥1 line of systemictherapy as compared to Investigator's choice of R-chemo or R-len. Recruitment started July 2025.AcknowledgementBMS Artificial Intelligence was used to revise existing text with human author oversight."

Clinical • P3 data • B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • CRBN • IKZF1